Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential by Espen Basmo Ellingsen, Espen Basmo Ellingsen, Espen Basmo Ellingsen, Sara M. Mangsbo, Sara M. Mangsbo, Eivind Hovig, Eivind Hovig, Gustav Gaudernack

Get full text

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial by Elin Aamdal, Elin Aamdal, Elin Aamdal, Else Marit Inderberg, Espen Basmo Ellingsen, Espen Basmo Ellingsen, Espen Basmo Ellingsen, Wenche Rasch, Paal Fredrik Brunsvig, Steinar Aamdal, Steinar Aamdal, Steinar Aamdal, Karen-Marie Heintz, Daniel Vodák, Sigve Nakken, Sigve Nakken, Eivind Hovig, Eivind Hovig, Marta Nyakas, Marta Nyakas, Tormod Kyrre Guren, Gustav Gaudernack, Gustav Gaudernack

Get full text

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma by Vilde Drageset Haakensen, Anna K. Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M. Cedres, Åslaug Helland

Get full text

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials by Sara M Mangsbo, Eivind Hovig, Nadia Mensali, Else Marit Inderberg, Steinar Aamdal, Elin Aamdal, Tormod Guren, Gustav Gaudernack, Espen Basmo Ellingsen, Wolfgang Lilleby, Paal F Brunsvig

Get full text

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination by Espen Basmo Ellingsen, Gergana Bounova, Iliana Kerzeli, Irantzu Anzar, Donjete Simnica, Elin Aamdal, Tormod Guren, Trevor Clancy, Artur Mezheyeuski, Else Marit Inderberg, Sara M. Mangsbo, Mascha Binder, Eivind Hovig, Gustav Gaudernack

Get full text